Alaunos Therapeutics (TCRT) Insider Trading & Ownership $1.77 -0.12 (-6.35%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.70 -0.08 (-4.24%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alaunos Therapeutics (NASDAQ:TCRT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.14%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$487.50KNumber OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$9.51K Get TCRT Insider Trade Alerts Want to know when executives and insiders are buying or selling Alaunos Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address TCRT Insider Buying and Selling by Quarter Alaunos Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/1/2023Kevin S Sr. BoyleCEOSell453$21.00$9,513.00 11/29/2022Robert W PostmaDirectorBuy5,000$97.50$487,500.00 (Data available from 1/1/2013 forward) TCRT Insider Trading Activity - Frequently Asked Questions Who is on Alaunos Therapeutics' Insider Roster? The list of insiders at Alaunos Therapeutics includes Kevin S Sr. Boyle, and Robert W Postma. Learn more on insiders at TCRT. What percentage of Alaunos Therapeutics stock is owned by insiders? 16.14% of Alaunos Therapeutics stock is owned by insiders. Learn more on TCRT's insider holdings. Which Alaunos Therapeutics insiders have been selling company stock? The following insider sold TCRT shares in the last 24 months: Kevin S Sr. Boyle ($9,513.00). How much insider selling is happening at Alaunos Therapeutics? Insiders have sold a total of 453 Alaunos Therapeutics shares in the last 24 months for a total of $9,513.00 sold. Alaunos Therapeutics Key ExecutivesMr. Dale Curtis Hogue Jr. (Age 54)Interim CEO & Director Ms. Melinda Lackey (Age 47)Senior VP of Legal, Administration & Secretary Compensation: $625.12kMr. Michael Wong (Age 44)Vice President of Finance & Principal Accounting Officer More Insider Trading Tools from MarketBeat Related Companies Calidi Biotherapeutics Insider Trades Edesa Biotech Insider Trades Athira Pharma Insider Trades X4 Pharmaceuticals Insider Trades Abpro Insider Trades Cyclacel Pharmaceuticals Insider Trades Marker Therapeutics Insider Trades Ainos Insider Trades AlloVir Insider Trades Lixte Biotechnology Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say BuyStrategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying This page (NASDAQ:TCRT) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access